• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥马环素对.临床分离株的活性。

activity of omadacycline against clinical isolates of .

机构信息

Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA.

Department of Pharmacy, University of Utah Health, Salt Lake City, Utah, USA.

出版信息

Antimicrob Agents Chemother. 2024 May 2;68(5):e0168623. doi: 10.1128/aac.01686-23. Epub 2024 Mar 27.

DOI:10.1128/aac.01686-23
PMID:38534103
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11064614/
Abstract

Nocardiosis typically requires a prolonged treatment duration of ≥6 months and initial combination therapy with 2-3 antibiotics. First-line regimens for nocardiosis are associated with considerable toxicity; therefore, alternative therapies are needed. Omadacycline is an aminomethylcycline with broad antimicrobial activity whose activity against species has not been formally assessed. The potency of omadacycline was evaluated against 300 clinical isolates by broth microdilution. The most common species tested were (21%), (20%), and (12%). The most common specimens were respiratory (178 isolates, 59%) and wound (57 isolates, 19%). Omadacycline minimum inhibitory concentrations (MICs) across all species ranged from 0.06 µg/mL to 8 µg/mL, with an MIC of 2 µg/mL and MIC of 4 µg/mL. The lowest MICs were found among (MIC = 0.25 µg/mL, MIC = 0.25 µg/mL), (MIC = 0.25 µg/mL, MIC = 1 µg/mL), complex (MIC = 0.5 µg/mL, MIC = 1 µg/mL), (MIC = 0.5 µg/mL, MIC = 2 µg/mL), and (MIC = 1 µg/mL, MIC = 2 µg/mL). The highest MICs were found among (MIC = 4 µg/mL, MIC = 8 µg/mL). potency differed by species among clinical isolates. Further studies are warranted to evaluate the potential clinical utility of omadacycline for nocardiosis.

摘要

奴卡菌病通常需要 ≥6 个月的长期治疗,并采用 2-3 种抗生素的初始联合治疗。奴卡菌病的一线治疗方案具有相当大的毒性;因此,需要替代疗法。奥马环素是一种具有广泛抗菌活性的氨甲基环素,其对 种的活性尚未经过正式评估。通过肉汤微量稀释法评估了奥马环素对 300 株临床分离株的抗菌活性。测试的最常见 种是 (21%)、 (20%)和 (12%)。最常见的标本是呼吸道 (178 株,59%)和伤口 (57 株,19%)。所有 种的奥马环素最低抑菌浓度 (MIC) 范围为 0.06 µg/mL 至 8 µg/mL,MIC 为 2 µg/mL,MIC 为 4 µg/mL。最低 MIC 见于 (MIC = 0.25 µg/mL,MIC = 0.25 µg/mL)、 (MIC = 0.25 µg/mL,MIC = 1 µg/mL)、 复合体 (MIC = 0.5 µg/mL,MIC = 1 µg/mL)、 (MIC = 0.5 µg/mL,MIC = 2 µg/mL)和 (MIC = 1 µg/mL,MIC = 2 µg/mL)。最高 MIC 见于 (MIC = 4 µg/mL,MIC = 8 µg/mL)。奥马环素对 临床分离株的抗菌活性因种而异。需要进一步的研究来评估奥马环素治疗奴卡菌病的潜在临床应用。

相似文献

1
activity of omadacycline against clinical isolates of .奥马环素对.临床分离株的活性。
Antimicrob Agents Chemother. 2024 May 2;68(5):e0168623. doi: 10.1128/aac.01686-23. Epub 2024 Mar 27.
2
Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species.台湾多中心研究:奈莫沙星、替加环素、多利培南和其他抗菌药物对各种诺卡氏菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2011 May;55(5):2084-91. doi: 10.1128/AAC.01808-10. Epub 2011 Feb 22.
3
Susceptibility Testing of Tedizolid against Isolates of Nocardia.替加环素对奴卡菌属分离株的药敏试验。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01537-17. Print 2017 Dec.
4
In vitro activity of fluoroquinolones against clinical isolates of Nocardia identified by partial 16S rRNA sequencing.通过16S rRNA部分测序鉴定的诺卡菌临床分离株对氟喹诺酮类药物的体外活性。
Eur J Clin Microbiol Infect Dis. 2008 Feb;27(2):115-20. doi: 10.1007/s10096-007-0413-2. Epub 2007 Nov 9.
5
Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018.对来自美国和欧洲的临床分离株进行奥马环素活性测试的监测:来自 SENTRY 抗菌监测计划的报告,2016 年至 2018 年。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02488-19.
6
Clinical features, identification, antimicrobial resistance patterns of Nocardia species in China: 2009-2017.中国诺卡氏菌属的临床特征、鉴定及抗菌药物耐药模式:2009-2017 年。
Diagn Microbiol Infect Dis. 2019 Jun;94(2):165-172. doi: 10.1016/j.diagmicrobio.2018.12.007. Epub 2018 Dec 29.
7
Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study.一项多中心研究显示,2014 年至 2017 年中国分离的细菌中,奥马环素的体外抗菌活性。
BMC Microbiol. 2020 Nov 16;20(1):350. doi: 10.1186/s12866-020-02019-8.
8
Nocardiosis at the turn of the century.世纪之交的诺卡菌病。
Medicine (Baltimore). 2009 Jul;88(4):250-261. doi: 10.1097/MD.0b013e3181afa1c8.
9
MLSA phylogeny and antimicrobial susceptibility of clinical Nocardia isolates: a multicenter retrospective study in China.MLSA 系统发育分析和临床诺卡菌分离株的药敏结果:中国多中心回顾性研究。
BMC Microbiol. 2021 Dec 13;21(1):342. doi: 10.1186/s12866-021-02412-x.
10
Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011.2010 - 2011年对来自全球范围(北美、欧洲、拉丁美洲、亚洲 - 西太平洋)的临床分离株进行的奥玛环素活性监测。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.00018-17. Print 2017 May.

引用本文的文献

1
New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on ).抗菌药物新视角:奥马环素用于社区获得性肺炎、皮肤及软组织感染和非结核分枝杆菌(重点论述)
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0108724. doi: 10.1128/aac.01087-24. Epub 2025 Jan 16.

本文引用的文献

1
Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease.奥马环素在中空纤维模型中的药代动力学/药效学及治疗肺部脓肿分枝杆菌病的疗效临床验证。
Int J Antimicrob Agents. 2023 Jul;62(1):106847. doi: 10.1016/j.ijantimicag.2023.106847. Epub 2023 May 13.
2
Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus Activity .奥马环素、依拉环素和替加环素对脓肿分枝杆菌表现出快速抑菌活性
Microbiol Spectr. 2023 Jun 15;11(3):e0071823. doi: 10.1128/spectrum.00718-23. Epub 2023 May 4.
3
Omadacycline for the treatment of infections: Case series and review of the literature.奥马环素用于治疗感染:病例系列及文献综述
IDCases. 2023 Jan 20;31:e01703. doi: 10.1016/j.idcr.2023.e01703. eCollection 2023.
4
Updated Review on Species: 2006-2021.物种更新综述:2006-2021 年。
Clin Microbiol Rev. 2022 Dec 21;35(4):e0002721. doi: 10.1128/cmr.00027-21. Epub 2022 Oct 31.
5
Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria.检测奥马环素对非结核分枝杆菌的药敏试验所面临的挑战及潜在解决方案。
Tuberculosis (Edinb). 2022 Dec;137:102269. doi: 10.1016/j.tube.2022.102269. Epub 2022 Oct 4.
6
Omadacycline Pharmacokinetics/Pharmacodynamics in the Hollow Fiber System Model and Potential Combination Regimen for Short Course Treatment of Mycobacterium kansasii Pulmonary Disease.奥马环素在中空纤维系统模型中的药代动力学/药效学及其在短程治疗堪萨斯分枝杆菌肺病的潜在联合方案。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0068722. doi: 10.1128/aac.00687-22. Epub 2022 Aug 17.
7
Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses.奥马环素在中空纤维系统模型中治疗肺部鸟分枝杆菌复合群的疗效和临床可达到的剂量下的效力。
J Antimicrob Chemother. 2022 May 29;77(6):1694-1705. doi: 10.1093/jac/dkac068.
8
Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline.口服四环素类药物在治疗成人皮肤和皮肤结构感染门诊患者中的应用:重点介绍多西环素、米诺环素和奥马环素。
Pharmacotherapy. 2021 Nov;41(11):915-931. doi: 10.1002/phar.2625. Epub 2021 Oct 5.
9
Preliminary, Real-world, Multicenter Experience With Omadacycline for Infections.奥马环素治疗感染的初步、真实世界、多中心经验
Open Forum Infect Dis. 2021 Jan 7;8(2):ofab002. doi: 10.1093/ofid/ofab002. eCollection 2021 Feb.
10
Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria.奥马环素对非结核分枝杆菌的药敏试验。
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01947-20.